{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:31:04Z","timestamp":1790101864454,"version":"4.0.1"},"reference-count":8,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2025,5,4]]},"DOI":"10.1080\/14712598.2025.2482663","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T15:18:22Z","timestamp":1742397502000},"page":"459-461","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Aflibercept biosimilars \u2013 so near, yet so far"],"prefix":"10.1080","volume":"25","author":[{"given":"Ashish","family":"Sharma","sequence":"first","affiliation":[{"name":"Lotus Eye Hospital and Institute","place":["Coimbatore, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Joon","family":"Woo","sequence":"additional","affiliation":[{"name":"Seoul National University Bundang Hospital, Seoul National University College of Medicine","place":["Seongnam, Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baruch D","family":"Kuppermann","sequence":"additional","affiliation":[{"name":"University of California","place":["Irvine, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,3,23]]},"reference":[{"key":"e_1_3_4_2_1","unstructured":"FDA approves Amgen\u2019s Pavblu\u2122 as fifth aflibercept biosimilar. [cited 2024 Oct 10]. Available from: https:\/\/www.lexology.com\/library\/detail.aspx?g=e930ee60-d2a7-4e8c-9d41-42adb9897a7f#:~:text=Pavblu%E2%84%A2%20is%20the%20fifth Yesafili%E2%84%A2%20(May%202024)"},{"key":"e_1_3_4_3_1","unstructured":"First aflibercept biosimilar approved in Korea as Samsung Bioepis\u2019 Afilivu\u00ae gets the green light. [cited 2024 Oct 10]. Available from: https:\/\/www.pearceip.law\/2024\/02\/26\/approval-alert-first-aflibercept-biosimilar-approved-in-korea-as-samsung-bioepis-afilivu-gets-the-green-light\/"},{"key":"e_1_3_4_4_1","unstructured":"Tyalia (Aflibercept). [cited 2025 Mar 21]. Available from: https:\/\/www.cinnagen.com\/Product.aspx?t=2&l=1&Id=609"},{"key":"e_1_3_4_5_1","unstructured":"Updates on aflibercept biosimilar approvals and BPCIA litigation. [cited 2024 Oct 10]. Available from: https:\/\/www.bigmoleculewatch.com\/2024\/06\/07\/updates-on-aflibercept-biosimilar-approvals-and-bpcia-litigation\/#:~:text=11%2C084%2C865%20(%E2%80%9Cthe%20\u2019865%20patent 11%2C084%2C865"},{"key":"e_1_3_4_6_1","unstructured":"Preliminary injunction against Amgen\u2019s EYLEA\u00ae biosimilar Pavblu\u2122 denied. [cited 2024 Oct 10]. Available from: https:\/\/www.jdsupra.com\/legalnews\/preliminary-injunction-against-amgen-s-3901618\/#:~:text=Numerous%20appeals%20are%20ongoing%20related of%20%245.72%20billion%20in%202023"},{"key":"e_1_3_4_7_1","unstructured":"Robbins R. How a drug company made $114 billion by gaming the U.S. Patent system. Available from: https:\/\/www.nytimes.com\/2023\/01\/28\/business\/humira-abbvie-monopoly.html"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02698-3"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2025.2482663","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T08:19:04Z","timestamp":1751876344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2025.2482663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,23]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,4]]}},"alternative-id":["10.1080\/14712598.2025.2482663"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2025.2482663","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-01-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}